Hikma has signaled a return to form for its generics business in 2023, forecasting 20% sales growth for the segment after a challenging 2022 that saw the segment’s turnover decline by 18%.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?